Literature DB >> 6148991

Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol.

A A Quyyumi, C Wright, L Mockus, K M Fox.   

Abstract

The use of beta adrenoceptor blockade in the treatment of rest angina is controversial, and the effects on severe angina of partial agonist activity in beta blockers are unknown. Eight patients with effort angina and seven with effort and nocturnal angina and severe coronary artery disease were studied initially when they were not taking any antianginal drugs. Pindolol 5 mg thrice daily (with partial agonist activity) and atenolol 100 mg daily (without partial agonist activity) were given for five days each in a double blind randomised manner. Diaries of angina were kept and treadmill exercise testing and ambulatory ST monitoring performed during the last 48 hours of each period of treatment. Daytime and nocturnal resting heart rates and the frequency of angina were significantly reduced by atenolol compared with pindolol (p less than 0.01). The duration of exercise was significantly increased and the frequency, duration, and magnitude of daytime and nocturnal episodes of ST segment depression on ambulatory monitoring were reduced by atenolol. Reduction in resting heart rate is important in the treatment of both effort and nocturnal angina. Partial agonist activity in beta adrenoceptor antagonists may be deleterious in patients with severe angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148991      PMCID: PMC1443147          DOI: 10.1136/bmj.289.6450.951

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

1.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity.

Authors:  W Frishman; J Kostis; J Strom; M Hossler; U Elkayam; S Goldner; R Silverman; R Davis; J Weinstein; E Sonnenblick
Journal:  Am Heart J       Date:  1979-10       Impact factor: 4.749

Review 2.  Partial agonist activity of beta-adrenergic blocking agents and cardiac performance: a review.

Authors:  A Reale; M Motolese
Journal:  Eur Heart J       Date:  1981-06       Impact factor: 29.983

3.  Pindolol and alprenolol in angina pectoris: a comparative clinical study.

Authors:  G Frithz; L Nordgren
Journal:  Curr Ther Res Clin Exp       Date:  1975-02

4.  "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients.

Authors:  A Maseri; S Severi; M D Nes; A L'Abbate; S Chierchia; M Marzilli; A M Ballestra; O Parodi; A Biagini; A Distante
Journal:  Am J Cardiol       Date:  1978-12       Impact factor: 2.778

5.  Acute influence of different beta-blocking agents upon left heart hemodynamics at rest and during exercise in patients with coronary artery disease.

Authors:  A Reale; A Nigri; P A Gioffrè; M Motolese
Journal:  Eur J Cardiol       Date:  1979-02

6.  Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol.

Authors:  G Jackson; J D Harry; C Robinson; D Kitson; D E Jewitt
Journal:  Br Heart J       Date:  1978-09

7.  Long-term benefit of cardioselective beta blockade with once-daily atenolol therapy in angina pectoris.

Authors:  J B Schwartz; G Jackson; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

8.  Exacerbation of vasotonic angina pectoris by propranolol.

Authors:  R M Robertson; A J Wood; W K Vaughn; D Robertson
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

9.  Propranolol and LB 46 (prinodolol) in angina pectoris. A comparative long-term ergometric study.

Authors:  M Arstila; V Kallio; H Wendelin
Journal:  Ann Clin Res       Date:  1973-04

10.  Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris.

Authors:  U Thadani; C Davidson; W Singleton; S H Taylor
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

View more
  21 in total

Review 1.  Silent myocardial ischaemia. Implications for therapy.

Authors:  N G Uren; D P Lipkin
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 2.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  Effect of partial agonist activity on the side effects of beta-blockade in patients with chronic stable angina.

Authors:  J Chambers; M L Ong; F Akhras; G Adam; G Jackson
Journal:  Drugs       Date:  1989       Impact factor: 9.546

5.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Silent ischaemia: clinical implications in 1988.

Authors:  K M Fox
Journal:  Br Heart J       Date:  1988-11

Review 7.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

8.  Reoperation for angina after previous aortocoronary bypass surgery.

Authors:  L J Freeman; P G Nixon
Journal:  Br Heart J       Date:  1985-11

9.  The total ischemic burden European trial (TIBET): design, methodology, and management. The TIBET Study Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

10.  Medical treatment of patients with severe exertional and rest angina: double blind comparison of beta blocker, calcium antagonist, and nitrate.

Authors:  A A Quyyumi; T Crake; C M Wright; L J Mockus; K M Fox
Journal:  Br Heart J       Date:  1987-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.